期刊文献+

刺络放血疗法治疗系统性硬化症临床观察 被引量:3

Clinical Observation of Therapy of Venesection for Blood-letting on Systemic Sclerosis
下载PDF
导出
摘要 目的:观察刺络放血疗法治疗系统性硬化症的临床疗效。方法:选取系统性硬化症患者44倒,随机分为观察组和对照组各22例,对照组口服沙立度胺和醋酸泼尼松片;观察组在对照组口服西药的基础上每周行两次刺络放血疗法。结果:观察组痊愈5例,显效12例,有效4例,无效1例,总有效率为95.45%(95%CI=77.2%~99.9%);对照组痊愈1例,显效10例,有效5例,无效6例,总有效率为72.73%(95%CI:49.8%~89.3%);两组综合疗效比较(u=2.2530,P=0.0247),差异有显著性意义;治疗后,观察组较对照组齿距增加(P〈0.05)、指距减小(P〈0.05)、全身皮肤积分、关节压痛指数、血沉参数均下降(P〈0.01)。结论:在西药治疗的基础上配合刺络放血疗法治疗系统性硬化症的疗效优于单纯口服西药,其收益为OR=0.13(95%CI=0.01~1.16),NNT=4(95%CI=2.26~90.91)。 Objective :To observe the clinical effect of therapy of veneseetion for blood -letting on systemic sclerosis. Method :44 cases with systemic sclerosis were randomly divided into two groups,22 cases in each group. All the cases were treated by Thalidomide and prednisone acetate tablets. Then the ones in treatment group were treated with venesection for blood -letting, two times in a week. Result:In treatment group 5 cases were cured, 12 ones excellent,4 ones effective,and 1 ones ineffective. The total effective rate was 95.45% (95% CI =77.2% - 99.9% ). In control group 1 cases were cured, 10 ones excellent,5 ones effective, and 6 ones ineffective. The total effective rate was 72.73 (95% CI =49.8% - 89. 3% ). There was significant difference on synthetic effect between the two groups (u = 2. 253 0, P = 0. 024 7 ). After treatment in treatment group thready gingival swelling was increased ( P 〈 0.05 ), span decreased ( P 〈 0. 05 ), and total skin score, joint tenderness index and ESR parameters were decreased (P 〈 0. 01 ). Conclusion:On the basis of western medicine treatment therapy of venesection for blood -letting has better effect on systemic sclerosis than only western medicine, OR = 0. 13 (95% CI = 0. 01 - 1.16) ,NNT=4 (95% CI=2.26-90.91).
出处 《山西中医》 2010年第2期28-30,共3页 Shanxi Journal of Traditional Chinese Medicine
关键词 系统性硬化症 拔罐 刺络放血疗法 systemic sclerosis, cupping, venesection for blood - letting
  • 相关文献

参考文献11

二级参考文献51

  • 1苏立德,颜纪贤.雷公藤多甙治疗系统性硬皮病临床观察[J].中国中西医结合杂志,1994,14(4):234-235. 被引量:21
  • 2张雷杰,张本法.高压氧综合治疗系统性硬皮病10例[J].中华航海医学杂志,1996,3(4):243-243. 被引量:3
  • 3赵国忠.硬皮病和硬肿病甲襞微循环分析[M].北京:人民卫生出版社,1987.94.
  • 4戴自英.实用内科学[M].北京:人民卫生出版社,1999..
  • 5中华风湿病学杂志编辑部.系统性硬皮病分期标准[J].中华风湿病学杂志,1998,2:66-66.
  • 6Reveille JD. Antibodies to centromere and centriole in scleroderma spectrum disorders. J Clin Invest, 1992, 89: 1208-1213.
  • 7Hu PQ, Fertig N, Medsger TA Jr. Molecular recognition patterns of serum anti-DNA topoisomerase I antibody in systemic sclerosis. J Immunol, 2004, 173: 2834.
  • 8Hall HI, Jamison P, Fulton JP. Reporting cutaneous melanoma to cancer registries in the United States. J Am Acad Dermatol, 2003,49: 624-630.
  • 9Lakos G, Takagawa S, Chen SJ, et al. Targeted disruption of TGF-beta/Smad3 signaling modulates skin fibrosis in a mouse model of seleroderma. Am J Pathol, 2004, 165: 203-217.
  • 10Hasegawa M, Sato S, Takehara K. Augmented production of transforming growth factor-beta by cultured peripheral blood mononuclear cells from patients with systemic sclerosis. ArchDermatol Res, 2004,296:89-93.

共引文献80

同被引文献31

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部